Science, health care and technology conglomerate Danaher said that it would buy molecular-diagnostics company Cepheid for $53.00 a share, in its first major acquisition since spinning off a large chunk of its business.
from WSJ.com: US Business http://ift.tt/2c492ag
via IFTTT
No comments:
Post a Comment